• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.一种与HLA - DR相关的、可被CD4 + T细胞识别的免疫显性SSX - 2衍生表位。
J Clin Invest. 2004 Apr;113(8):1225-33. doi: 10.1172/JCI20667.
2
Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.SSX-2 蛋白 37-58 区域中不同但相互重叠的辅助性 T 细胞表位。
Clin Immunol. 2005 Jan;114(1):70-8. doi: 10.1016/j.clim.2004.08.014.
3
Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.在黑色素瘤患者对抗原表达肿瘤的免疫反应过程中，肿瘤反应性、SSX - 2特异性CD8 + T细胞被选择性扩增。
Cancer Res. 2003 Sep 1;63(17):5601-6.
4
Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.用重组NY-ESO-1蛋白进行疫苗接种可引发具有保守T细胞受体库的免疫显性HLA-DR52b限制性CD4 + T细胞反应。
Clin Cancer Res. 2009 Jul 1;15(13):4467-74. doi: 10.1158/1078-0432.CCR-09-0582. Epub 2009 Jun 16.
5
NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.NY-ESO-1 119-143是一种可被Th1型和Th2型肿瘤反应性CD4 + T细胞识别的多反应性主要组织相容性复合体II类T辅助表位。
Cancer Res. 2002 Jan 1;62(1):213-8.
6
Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.滑膜肉瘤X（SSX）抗原在上皮性卵巢癌中的表达及CD4 + T细胞识别的SSX - 4表位的鉴定。
Clin Cancer Res. 2006 Jan 15;12(2):398-404. doi: 10.1158/1078-0432.CCR-05-1902.
7
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.NY-ESO-1编码被黑色素瘤反应性CD4 + T细胞识别的DRB1*0401限制性表位。
Cancer Res. 2000 Sep 1;60(17):4946-52.
8
Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.肝细胞癌患者中CD4 + T细胞对一种新型甲胎蛋白衍生表位的反应分析
Clin Cancer Res. 2005 Sep 15;11(18):6686-94. doi: 10.1158/1078-0432.CCR-05-0382.
9
Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.源自凋亡抑制蛋白survivin的一种多反应性HLA DR限制性T细胞表位的鉴定
Hum Immunol. 2007 Jul;68(7):572-6. doi: 10.1016/j.humimm.2007.03.007. Epub 2007 Apr 11.
10
CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope.来自健康受试者和结肠癌患者的CD4(+) T细胞识别癌胚抗原特异性免疫显性表位。
Cancer Res. 2003 Dec 1;63(23):8481-6.

引用本文的文献

1
Circulating Exhausted PD-1CD39 Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade.循环耗竭的PD-1⁺CD39⁺辅助性CD4⁺ T细胞具有肿瘤抗原特异性，并可预测对PD-1/PD-L1轴阻断的反应。
Cancers (Basel). 2022 Jul 28;14(15):3679. doi: 10.3390/cancers14153679.
2
Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.治疗性癌症疫苗——抗原发现与佐剂递送平台
Pharmaceutics. 2022 Jul 11;14(7):1448. doi: 10.3390/pharmaceutics14071448.
3
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.PD-1 阻断恢复了浸润肿瘤的衰竭 PD-1hiCD39+ CD4 T 细胞的辅助活性。
JCI Insight. 2021 Jan 25;6(2):142513. doi: 10.1172/jci.insight.142513.
4
Molecular and genetic properties of tumors associated with local immune cytolytic activity.与局部免疫细胞溶解活性相关的肿瘤的分子和遗传特性。
Cell. 2015 Jan 15;160(1-2):48-61. doi: 10.1016/j.cell.2014.12.033.
5
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.细胞毒性 T 淋巴细胞同时靶向多个肿瘤相关抗原治疗 EBV 阴性淋巴瘤。
Mol Ther. 2011 Dec;19(12):2258-68. doi: 10.1038/mt.2011.167. Epub 2011 Sep 13.
6
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.针对癌症睾丸抗原 SSX-2 的疫苗可引发 HLA-A2 表位特异性细胞毒性 T 细胞。
J Immunother. 2011 Oct;34(8):569-80. doi: 10.1097/CJI.0b013e31822b5b1d.
7
Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.鉴定 HLA-DPB1*0501 限制性 Melan-A/MART-1 表位，该表位被 CD4+ T 淋巴细胞识别：亚洲人群免疫治疗的流行率。
J Immunother. 2011 Sep;34(7):525-34. doi: 10.1097/CJI.0b013e318226bd45.
8
The SSX family of cancer-testis antigens as target proteins for tumor therapy.作为肿瘤治疗靶蛋白的癌-睾丸抗原SSX家族。
Clin Dev Immunol. 2010;2010:150591. doi: 10.1155/2010/150591. Epub 2010 Oct 11.
9
An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain.一例对化疗和免疫疗法敏感的转移性黑色素瘤罕见病例，脑部出现晚期免疫逃逸。
Cancer Immun. 2008 Mar 27;8:6.
10
Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals.对无癌个体中肿瘤抗原SSX - 1特异性CD4 + T细胞的评估。
Cancer Immunol Immunother. 2007 Aug;56(8):1183-92. doi: 10.1007/s00262-006-0269-9. Epub 2006 Dec 22.

本文引用的文献

1
SSX antigens as tumor vaccine targets in human sarcoma.SSX抗原作为人类肉瘤中的肿瘤疫苗靶点。
Cancer Immun. 2003 Oct 9;3:13.
2
Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.在黑色素瘤患者对抗原表达肿瘤的免疫反应过程中，肿瘤反应性、SSX - 2特异性CD8 + T细胞被选择性扩增。
Cancer Res. 2003 Sep 1;63(17):5601-6.
3
Cancer/testis (CT) antigens - a new link between gametogenesis and cancer.癌胚/睾丸（CT）抗原——配子发生与癌症之间的新联系。
Cancer Immun. 2001 Mar 30;1:1.
4
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.癌胚抗原：癌症免疫治疗中不断扩大的靶点家族。
Immunol Rev. 2002 Oct;188:22-32. doi: 10.1034/j.1600-065x.2002.18803.x.
5
Use of class II tetramers for identification of CD4+ T cells.使用II类四聚体鉴定CD4+ T细胞。
J Immunol Methods. 2002 Oct 1;268(1):71-81. doi: 10.1016/s0022-1759(02)00201-6.
6
Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity.基于组合肽库鉴定未知特异性的肿瘤反应性细胞溶解性T淋巴细胞的肽配体。
Eur J Immunol. 2002 Aug;32(8):2292-9. doi: 10.1002/1521-4141(200208)32:8<2292::AID-IMMU2292>3.0.CO;2-K.
7
Tracking T cells with tetramers: new tales from new tools.用四聚体追踪T细胞：新工具带来的新故事。
Nat Rev Immunol. 2002 Apr;2(4):263-72. doi: 10.1038/nri777.
8
Expression of SSX genes in human osteosarcomas.SSX基因在人骨肉瘤中的表达。
Int J Cancer. 2002 Apr 1;98(4):640-2. doi: 10.1002/ijc.10277.
9
Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.蛋白酶体辅助鉴定出一种由SSX-2衍生的表位，该表位可被浸润转移性黑色素瘤的肿瘤反应性细胞毒性T淋巴细胞识别。
J Immunol. 2002 Feb 15;168(4):1717-22. doi: 10.4049/jimmunol.168.4.1717.
10
Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay.通过干扰素-γ捕获试验富集T淋巴细胞的过继性肿瘤治疗。
Nat Med. 2001 Oct;7(10):1159-62. doi: 10.1038/nm1001-1159.

一种与HLA - DR相关的、可被CD4 + T细胞识别的免疫显性SSX - 2衍生表位。

An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.

作者信息

Ayyoub Maha, Hesdorffer Charles S, Montes Monica, Merlo Andrea, Speiser Daniel, Rimoldi Donata, Cerottini Jean-Charles, Ritter Gerd, Scanlan Matthew, Old Lloyd J, Valmori Danila

机构信息

Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

出版信息

J Clin Invest. 2004 Apr;113(8):1225-33. doi: 10.1172/JCI20667.

DOI:10.1172/JCI20667
PMID:15085202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC385406/
Abstract

Ectopic gene expression in tumors versus normal somatic tissues provides opportunities for the specific immunotargeting of cancer cells. SSX gene products are expressed in tumors of different histological types and can be recognized by tumor-reactive CTLs from cancer patients. Here, we report the identification of an SSX-2-derived immunodominant T cell epitope recognized by CD4(+) T cells from melanoma patients in association with HLA-DR. The epitope maps to the 37-58 region of the protein, encompassing the sequence of the previously defined HLA-A2-restricted immunodominant epitope SSX-2(41-49). SSX-2(37-58)-specific CD4(+) T cells were detected among circulating lymphocytes from the majority of melanoma patients analyzed and among tumor-infiltrating lymphocytes, but not in healthy donors. Together, our data suggest a dominant role of the 37-58 sequence in the induction of cellular CD4(+) T cell responses against SSX antigens and will be instrumental for both the onset and the monitoring of upcoming cancer-vaccine trials using SSX-derived immunogens.

摘要

肿瘤与正常体细胞组织中的异位基因表达为癌细胞的特异性免疫靶向提供了机会。SSX基因产物在不同组织学类型的肿瘤中表达，并且可被癌症患者的肿瘤反应性CTL识别。在此，我们报告了鉴定出一个源自SSX-2的免疫显性T细胞表位，该表位可被黑色素瘤患者的CD4(+) T细胞与HLA-DR结合识别。该表位定位于蛋白质的37-58区域，包含先前定义的HLA-A2限制性免疫显性表位SSX-2(41-49)的序列。在分析的大多数黑色素瘤患者的循环淋巴细胞以及肿瘤浸润淋巴细胞中检测到了SSX-2(37-58)特异性CD4(+) T细胞，但在健康供体中未检测到。总之，我们的数据表明37-58序列在诱导针对SSX抗原的细胞CD4(+) T细胞反应中起主导作用，并且对于使用源自SSX的免疫原进行即将到来的癌症疫苗试验的启动和监测都将有帮助。